Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price fell 23.5% on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares changed hands during trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Trading Down 23.5%
The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The company has a market cap of C$19.27 million, a PE ratio of -4.64 and a beta of 0.67. The business has a 50 day simple moving average of C$0.16 and a two-hundred day simple moving average of C$0.17.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Featured Stories
- Five stocks we like better than Devonian Health Group
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- Asset Allocation Strategies in Volatile Markets
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Most Volatile Stocks, What Investors Need to Know
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
